IBDEI1GY ; ; 04-FEB-2020
 ;;3.0;IB ENCOUNTER FORM IMP/EXP;;FEB 04, 2020
 Q:'DIFQR(358.3)  F I=1:2 S X=$T(Q+I) Q:X=""  S Y=$E($T(Q+I+1),4,999),X=$E(X,4,999) S:$A(Y)=126 I=I+1,Y=$E(Y,2,999)_$E($T(Q+I+1),5,999) S:$A(Y)=61 Y=$E(Y,2,999) X NO E  S @X=Y
Q Q
 ;;^UTILITY(U,$J,358.3,23494,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,23494,1,3,0)
 ;;=3^High Risk Sexual Behaviors
 ;;^UTILITY(U,$J,358.3,23494,1,4,0)
 ;;=4^Z72.51
 ;;^UTILITY(U,$J,358.3,23494,2)
 ;;=^5063258
 ;;^UTILITY(U,$J,358.3,23495,0)
 ;;=B16.9^^105^1174^39
 ;;^UTILITY(U,$J,358.3,23495,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,23495,1,3,0)
 ;;=3^Hepatitis B, acute
 ;;^UTILITY(U,$J,358.3,23495,1,4,0)
 ;;=4^B16.9
 ;;^UTILITY(U,$J,358.3,23495,2)
 ;;=^5000540
 ;;^UTILITY(U,$J,358.3,23496,0)
 ;;=B18.1^^105^1174^40
 ;;^UTILITY(U,$J,358.3,23496,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,23496,1,3,0)
 ;;=3^Hepatitis B, chronic without coma
 ;;^UTILITY(U,$J,358.3,23496,1,4,0)
 ;;=4^B18.1
 ;;^UTILITY(U,$J,358.3,23496,2)
 ;;=^5000547
 ;;^UTILITY(U,$J,358.3,23497,0)
 ;;=B17.10^^105^1174^42
 ;;^UTILITY(U,$J,358.3,23497,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,23497,1,3,0)
 ;;=3^Hepatitis C, acute
 ;;^UTILITY(U,$J,358.3,23497,1,4,0)
 ;;=4^B17.10
 ;;^UTILITY(U,$J,358.3,23497,2)
 ;;=^5000542
 ;;^UTILITY(U,$J,358.3,23498,0)
 ;;=B18.2^^105^1174^43
 ;;^UTILITY(U,$J,358.3,23498,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,23498,1,3,0)
 ;;=3^Hepatitis C, chronic without coma
 ;;^UTILITY(U,$J,358.3,23498,1,4,0)
 ;;=4^B18.2
 ;;^UTILITY(U,$J,358.3,23498,2)
 ;;=^5000548
 ;;^UTILITY(U,$J,358.3,23499,0)
 ;;=J11.1^^105^1174^73
 ;;^UTILITY(U,$J,358.3,23499,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,23499,1,3,0)
 ;;=3^Influenza
 ;;^UTILITY(U,$J,358.3,23499,1,4,0)
 ;;=4^J11.1
 ;;^UTILITY(U,$J,358.3,23499,2)
 ;;=^5008158
 ;;^UTILITY(U,$J,358.3,23500,0)
 ;;=A92.30^^105^1174^180
 ;;^UTILITY(U,$J,358.3,23500,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,23500,1,3,0)
 ;;=3^West Nile
 ;;^UTILITY(U,$J,358.3,23500,1,4,0)
 ;;=4^A92.30
 ;;^UTILITY(U,$J,358.3,23500,2)
 ;;=^5000443
 ;;^UTILITY(U,$J,358.3,23501,0)
 ;;=A41.4^^105^1174^137
 ;;^UTILITY(U,$J,358.3,23501,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,23501,1,3,0)
 ;;=3^Sepsis d/t Anaerobes
 ;;^UTILITY(U,$J,358.3,23501,1,4,0)
 ;;=4^A41.4
 ;;^UTILITY(U,$J,358.3,23501,2)
 ;;=^5000206
 ;;^UTILITY(U,$J,358.3,23502,0)
 ;;=Z16.30^^105^1174^68
 ;;^UTILITY(U,$J,358.3,23502,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,23502,1,3,0)
 ;;=3^Infection with drug-resistant organism
 ;;^UTILITY(U,$J,358.3,23502,1,4,0)
 ;;=4^Z16.30
 ;;^UTILITY(U,$J,358.3,23502,2)
 ;;=^5062737
 ;;^UTILITY(U,$J,358.3,23503,0)
 ;;=B96.4^^105^1174^126
 ;;^UTILITY(U,$J,358.3,23503,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,23503,1,3,0)
 ;;=3^Proteus spp. (other)
 ;;^UTILITY(U,$J,358.3,23503,1,4,0)
 ;;=4^B96.4
 ;;^UTILITY(U,$J,358.3,23503,2)
 ;;=^5000853
 ;;^UTILITY(U,$J,358.3,23504,0)
 ;;=B96.5^^105^1174^127
 ;;^UTILITY(U,$J,358.3,23504,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,23504,1,3,0)
 ;;=3^Pseudomonas spp.(other)
 ;;^UTILITY(U,$J,358.3,23504,1,4,0)
 ;;=4^B96.5
 ;;^UTILITY(U,$J,358.3,23504,2)
 ;;=^5000854
 ;;^UTILITY(U,$J,358.3,23505,0)
 ;;=B95.8^^105^1174^149
 ;;^UTILITY(U,$J,358.3,23505,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,23505,1,3,0)
 ;;=3^Staphylococcus aureus, methicillin-susceptible
 ;;^UTILITY(U,$J,358.3,23505,1,4,0)
 ;;=4^B95.8
 ;;^UTILITY(U,$J,358.3,23505,2)
 ;;=^5000844
 ;;^UTILITY(U,$J,358.3,23506,0)
 ;;=B95.61^^105^1174^148
 ;;^UTILITY(U,$J,358.3,23506,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,23506,1,3,0)
 ;;=3^Staphylococcus aureus, methicillin-resistant
 ;;^UTILITY(U,$J,358.3,23506,1,4,0)
 ;;=4^B95.61
